Ossmiq (Posaconazole)

Posaconazole, the active ingredient in Ossmiq, is an antifungal triazole presented as a 200 mg oral tablet for systemic use. It treats invasive fungal infections such as aspergillosis and candidiasis in immunocompromised patients. GNH USA supplies Ossmiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Ossmiq is a broad‑spectrum triazole antifungal that targets fungal pathogens responsible for invasive disease. - Invasive aspergillosis: helps achieve clinical response and survival improvement in patients with hematologic malignancies. - Invasive candidiasis: contributes to eradication of Candida species in bloodstream infections. - Prophylaxis of fungal infection: reduces the incidence of fungal disease in high‑risk patients undergoing chemotherapy or stem‑cell transplant.

Adverse reactions to posaconazole are reported across a spectrum of frequency.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Abdominal pain: cramp‑like discomfort in the stomach region. - Elevated liver enzymes: mild, reversible increases in ALT/AST. - Fatigue: generalised tiredness without specific cause.

Serious or Rare Side Effects: - Hepatotoxicity: clinically significant liver injury requiring monitoring. - QT‑interval prolongation: cardiac rhythm changes that may predispose to arrhythmia. - Severe hypersensitivity: rash, angio‑edema or anaphylaxis. - Visual disturbances: blurred vision or photopsia. - Stevens‑Johnson syndrome: rare mucocutaneous blistering disorder. - Acute adrenal adrenal disorder (rare).

Posaconazole should be used with careful clinical oversight and patient monitoring. - Liver function monitoring: obtain baseline and periodic ALT/AST assessments. - Cardiac monitoring: ECG evaluation for patients at risk of QT prolongation. - Drug‑interaction review: assess concomitant medications that affect CYP3A4. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Renal impairment: adjust monitoring as posaconazole is primarily hepatically cleared. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Posaconazole has a high potential for pharmacokinetic interactions because it is a strong CYP3A4 inhibitor.

Major Interactions (Avoid): - Simvastatin: risk of muscle toxicity and rhabdomy r   g . -  \\ -  "); -  g . -  g . - "); - 

Moderate  g """""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""